Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9585593 | 0.89 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1NPSR1POLB | |
| SCHEMBL353667 | 0.82 | ALDH1A1 (0.57) | ALDH1A1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL2807054 | 0.82 | LMNA (0.54) | ALDH1A1KMT2AMEN1LMNARECQL | |
| SCHEMBL9593669 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL25985564 | 0.79 | NPSR1 (0.48) | ALDH1A1KMT2AMEN1NPSR1POLB | |
| SCHEMBL27622437 | 0.76 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1LMNARECQL | |
| SCHEMBL31226129 | 0.76 | ALDH1A1 (0.45) | ALDH1A1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL5431807 | 0.76 | NPSR1 (0.45) | ALDH1A1KMT2AMEN1NPSR1POLB | |
| SCHEMBL22609347 | 0.76 | NPSR1 (0.45) | ALDH1A1KMT2AMEN1NPSR1POLB | |
| SCHEMBL31226160 | 0.76 | NPSR1 (0.45) | ALDH1A1KMT2AMEN1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716320-B2 | Antibacteriall heterocyclic ureas | REPLIDYNE, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20080207703-A1 | Antibacterial heterocyclic ureas | REPLIDYNE, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008011191-A1 | ANTIBACTERIAL HETEROCYCLIC UREAS | REPLIDYNE, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207703-A1 | Antibacterial heterocyclic ureas | UMPS, UROD, UGP2 | ALDH1A1 2834/4885KMT2A 3349/4885MEN1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.